Can Placebo Therapy Influence Arterial Blood Pressure?

1981 ◽  
Vol 61 (s7) ◽  
pp. 487s-490s ◽  
Author(s):  
B. A. Gould ◽  
S. Mann ◽  
A. B. Davies ◽  
D. G. Altman ◽  
E. B. Raftery
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Antihypertensive Effect ◽  
No Reduction ◽  
Controlled Trial ◽  
Controlled Clinical Trial ◽  
Clinic Blood Pressure ◽  
Double Blind ◽  
Arterial Blood ◽  
Minimal Reduction

1. With standard sphygmomanometric techniques used in conjunction with continuous intra-arterial monitoring the antihypertensive effect of placebo was examined in a group of patients participating in a controlled clinical trial. 2. Twelve of the 20 patients entered completed all stages of a randomized double-blind controlled trial of placebo and indoramin. Clinic blood pressure in patients receiving placebo showed reductions which were highly significant (P < 0.001). Simultaneous intra-arterial monitoring showed no reduction of the blood pressure over the 24 h studied. 3. The clinic pressures showed minimal reduction of blood pressure in response to indoramin therapy whereas intra-arterial pressures showed a significant fall (P < 0.01). 4. The response of the blood pressure to placebo appears to be an artifact of the indirect sphygmomanometric method and its use as a control in this study led to under-estimation of the efficacy of indoramin.

scholarly journals Pramipexole in peritoneal dialysis patients with restless legs syndrome (RLS): a protocol for a multicentre double-blind randomised controlled trial

BMJ Open ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. e033815
Author(s):  
Tian-tian Ma ◽  
Zhikai Yang ◽  
Sainan Zhu ◽  
Jing-hong Zhao ◽  
Yi Li ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Peritoneal Dialysis ◽  
Restless Legs Syndrome ◽  
Rating Scale ◽  
Controlled Trial ◽  
Psychological Status ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Restless Legs ◽  
Peking University

IntroductionRestless legs syndrome (RLS) is a common neurological sensorimotor disorder among patients with end stage renal disease. This clinical trial aimed to provide evidence on the efficacy and safety of pramipexole in patients with uremic RLS receiving peritoneal dialysis (PD).Methods and analysisThis is a 12-week, multicentre, randomised, double-blind, placebo-controlled clinical trial. In total, 104 patients with uremic RLS receiving PD will be enrolled from four hospitals and randomly assigned in a 1:1 ratio to either placebo or pramipexole. We will determine the efficacy of pramipexole in the improvement of International RLS Study Group Rating Scale as the primary outcome, while responder rates for other RLS scales at week 12, change from baseline to week 12 for psychological status, sleep disorder and quality of life and blood pressure represent the secondary outcomes.Ethics and disseminationThe study was approved by the ethics committees of Peking University First Hospital, Xinqiao hospital of Army Medical University, Cangzhou Center Hospital and Peking University Shenzhen Hospital. The results will be disseminated in peer-reviewed journals.Trial registration numberNCT03817554

scholarly journals Blueberries Improve Endothelial Function, but Not Blood Pressure, in Adults with Metabolic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Nutrients ◽  
2015 ◽  
Vol 7 (6) ◽  
pp. 4107-4123 ◽  
Author(s):  
April Stull ◽  
Katherine Cash ◽  
Catherine Champagne ◽  
Alok Gupta ◽  
Raymond Boston ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Endothelial Function ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

Effect of Probiotic Supplementation on Blood Pressure of Females with Gestational Diabetes Mellitus: A Randomized Double Blind Controlled Clinical Trial

2017 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Majid Hajifaraji ◽  
Fatemeh Jahanjou ◽  
Fatemeh Abbasalizadeh ◽  
Naser Aghamohammadzadeh ◽  
Mehran Mesgari Abbasi ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Blood Pressure ◽  
Clinical Trial ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Controlled Clinical Trial ◽  
Probiotic Supplementation ◽  
Double Blind

Effects of N-acetylcysteine on substance use in bipolar disorder: A randomised placebo-controlled clinical trial

2009 ◽  
Vol 21 (6) ◽  
pp. 285-291 ◽  
Author(s):  
Michelle Bernardo ◽  
Seetal Dodd ◽  
Clarissa S. Gama ◽  
David L Copolov ◽  
Olivia Dean ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Bipolar Disorder ◽  
Substance Use ◽  
Controlled Trial ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Other Substances

Objective:To evaluate the effect of N-acetylcysteine (NAC) on substance use in a double-blind, placebo-controlled trial of NAC in bipolar disorder. It is hypothesised that NAC will be superior to placebo for reducing scores on the Clinical Global Impressions scale for Substance Use (CGI-SU).Methods:Participants were randomised to a 6-months of treatment with 2 g/day NAC (n = 38) or placebo (n = 37). Substance use was assessed at baseline using a Habits instrument. Change in substance use was assessed at regular study visits using the CGI-SU.Results:Among the 75 participants 78.7% drank alcohol (any frequency), 45.3% smoked tobacco and 92% consumed caffeine. Other substances were used by fewer than six participants. Caffeine use was significantly lower for NAC-treated participants compared to placebo at week 2 of treatment but not at other study visits.Conclusions:NAC appeared to have little effect on the participants who were using substances. A larger study on a substance-using population will be necessary to determine if NAC may be a useful treatment for substance use.

scholarly journals Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Ying Zhao ◽  
Yuan-Yuan Yang ◽  
Bao-Lin Yang ◽  
Ya-Wei Du ◽  
Da-Wei Ren ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Controlled Trial ◽  
Density Lipoprotein ◽  
Lipid Lowering ◽  
Controlled Clinical Trial ◽  
Atherosclerotic Cardiovascular Disease ◽  
Efficacy And Safety ◽  
Clinical Trial Registry ◽  
High Quality ◽  
Double Blind

Abstract Background Dyslipidemia is a major risk factor for atherosclerotic cardiovascular disease and a leading cause of death worldwide. The clinical utility of commonly used lipid-lowering drugs such as statins and fibrates is sometimes limited by the occurrence of various adverse reactions. Recently, berberine (BBR) has received increasing attention as a safer and more cost-effective option to manage dyslipidemia. Thus, a high-quality randomized controlled trial to evaluate the efficacy and safety of BBR in the treatment of dyslipidemia is deemed necessary. Methods/design This is a randomized, double-blind, and placebo-controlled clinical trial. A total of 118 patients with dyslipidemia will be enrolled in this study and randomized into two groups at a ratio of 1:1. BBR or placebo will be taken orally for 12 weeks. The primary outcome is the percentage of low-density lipoprotein cholesterol reduction at week 12. Other outcome measures include changes in other lipid profiles, high sensitivity C-reactive protein, blood pressure, body weight, Bristol Stool Chart, traditional Chinese medicine symptom form, adipokine profiles, and metagenomics of intestinal microbiota. Safety assessment includes general physical examination, blood and urine routine test, liver and kidney function test, and adverse events. Discussion This trial may provide high-quality evidence on the efficacy and safety of BBR for dyslipidemia. Importantly, the findings of this trial will help to identify patient and disease characteristics that may predict favorable outcomes of treatment with BBR and optimize its indication for clinical use. Trial registration Chinese Clinical Trial Registry ChiCTR1900021361. Registered on 17 February 2019.

Blood pressure lowering and anti-inflammatory effects of hesperidin in type 2 diabetes; a randomized double-blind controlled clinical trial

2018 ◽  
Vol 32 (6) ◽  
pp. 1073-1079 ◽  
Author(s):  
Fatemeh Homayouni ◽  
Fatemeh Haidari ◽  
Mehdi Hedayati ◽  
Mehrnoosh Zakerkish ◽  
Kambiz Ahmadi
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
Blood Pressure Lowering ◽  
Double Blind ◽  
Pressure Lowering ◽  
Anti Inflammatory

scholarly journals Randomized double-blind controlled clinical trial of the blood pressure–lowering effect of fermented milk with Lactococcus lactis: A pilot study

2018 ◽  
Vol 101 (4) ◽  
pp. 2819-2825 ◽  
Author(s):  
Lilia M. Beltrán-Barrientos ◽  
Aarón F. González-Córdova ◽  
Adrián Hernández-Mendoza ◽  
Eduardo H. Torres-Inguanzo ◽  
Humberto Astiazarán-García ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Pilot Study ◽  
Lactococcus Lactis ◽  
Fermented Milk ◽  
Controlled Clinical Trial ◽  
Blood Pressure Lowering ◽  
Blood Pressure Lowering Effect ◽  
Double Blind ◽  
Pressure Lowering
Sign in / Sign up

Export Citation Format

Share Document